Represented Flying L Partners in connection with its investment in the $93 million Series B financing of Oyster Point Pharma, Inc. Flying L Partners co-led the financing with Invus Opportunities. Falcon Vision, New Enterprise Associates, Versant Ventures, and Vida Ventures also participated in the round. Read the press release.
Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company's initial focus is to develop innovative therapeutics to treat the signs and symptoms of dry eye disease by stimulating the trigeminal parasympathetic pathway to activate the glands and cells responsible for tear film production.
The Newport Beach-based deal team representing Flying L was led by Bruce Feuchter, with Jeff Estes advising the client on Oyster Point financing-related matters, and Ryan Gaglio advising the client on fund formation matters.